Drug Profile
GI 4000
Alternative Names: GI-4000Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator GlobeImmune
- Developer GlobeImmune; ImmunityBio
- Class Cancer vaccines
- Mechanism of Action Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Colorectal cancer; Pancreatic cancer; Triple negative breast cancer
- Suspended Non-small cell lung cancer; Solid tumours
Most Recent Events
- 09 Mar 2021 NantKwest has been merged with ImmunityBio to form ImmunityBio
- 18 Sep 2020 Phase I/II is still ongoing in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) is still ongoing in USA (SC) (NCT03563157)
- 27 Sep 2019 Efficacy and adverse events data from the phase I/II QUILT-3.067 trial in Breast cancer presented at the 44th European Society for Medical Oncology Congress (ESMO-2019)